Emergent Biosolutions Inc. (NYSE:EBS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Emergent Biosolutions Inc. (NYSE:EBS) have been given an average recommendation of “Hold” by the five research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $12.00.

EBS has been the topic of several analyst reports. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings cut Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. HC Wainwright dropped their target price on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd.

Insiders Place Their Bets

In other news, Director Sujata Tyagi Dayal sold 13,761 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $115,592.40. Following the sale, the director directly owned 100,563 shares in the company, valued at $844,729.20. This trade represents a 12.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Donald W. Degolyer sold 15,481 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total value of $130,040.40. Following the sale, the director owned 129,721 shares in the company, valued at $1,089,656.40. This trade represents a 10.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,925 shares of company stock valued at $518,312 over the last quarter. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On Emergent Biosolutions

Several institutional investors have recently bought and sold shares of EBS. Legal & General Group Plc acquired a new stake in Emergent Biosolutions in the 2nd quarter worth about $31,000. Torren Management LLC acquired a new stake in Emergent Biosolutions in the 4th quarter worth about $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions in the 4th quarter worth about $45,000. Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions in the 2nd quarter worth about $53,000. Finally, Farther Finance Advisors LLC boosted its holdings in Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 4,827 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions Price Performance

Shares of EBS opened at $7.99 on Tuesday. The business’s 50-day moving average is $8.41 and its two-hundred day moving average is $10.02. The company has a market capitalization of $412.39 million, a P/E ratio of -28.54 and a beta of 2.33. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. Emergent Biosolutions has a fifty-two week low of $5.61 and a fifty-two week high of $14.06.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.46. The company had revenue of $156.10 million for the quarter, compared to the consensus estimate of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.